Condition (MeSH)
Anemia, Hemolytic, Autoimmune
ClinicalTrials.gov lists 83 trials for Anemia, Hemolytic, Autoimmune or a narrower condition beneath it. Bioverativ, a Sanofi company has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
83 of the 83 trials are tagged with Anemia, Hemolytic, Autoimmune itself; the rest are tagged with a narrower condition beneath it.
When did Anemia, Hemolytic, Autoimmune trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 17
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 11 |
| 2025 | 17 |
| 2024 | 4 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 6 |
| 2018 | 4 |
| 2017 | 3 |
Showing 10 of 25 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 14 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 15 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 33 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Anemia, Hemolytic, Autoimmune trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 28 |
| Phase 1/2 | 4 |
| Phase 2 | 19 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 20 |
How many Anemia, Hemolytic, Autoimmune trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 16 |
| Recruiting | 22 |
| Active, not recruiting | 4 |
| Completed | 27 |
| Terminated | 4 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Anemia, Hemolytic, Autoimmune trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bioverativ, a Sanofi company | 5 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 |
| Juventas Cell Therapy Ltd. | 2 |
| Sanofi | 2 |
| Alpine Immune Sciences Inc, A Subsidiary of Vertex | 1 |
Which drugs are being tested for Anemia, Hemolytic, Autoimmune? (9)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sutimlimab | 4 |
| RITUXIMAB | 3 |
| Cytoxan | 3 |
| IBRUTINIB | 2 |
| Iptacopan | 2 |
Showing 5 of 9 drugs.
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| YTS109 cell | 3 |
| BLOOD SAMPLE | 3 |
| Filgrastime (G-CSF) | 2 |
| universal allogeneic anti-CD19/BCMA CAR T-cells | 2 |
| SQ Fludarabine | 2 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Anemia, Hemolytic, Autoimmune trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Autoimmune haemolytic anaemia | 6 | 3 |
| COVID-19 pneumonia | 4 | 2 |
| Acute kidney injury | 3 | 2 |
| Blood creatinine increased | 3 | 2 |
| COVID-19 | 3 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Anemia, Hemolytic, Autoimmune? (115)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial. | American journal of hematology | 2026 | Yes |
| CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia. | The New England journal of medicine | 2026 | Yes |
| Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response Analyses. | Clinical pharmacology and therapeutics | 2025 | Yes |
| Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia. | Blood | 2025 | Yes |
| Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study. | The Lancet. Haematology | 2025 | Yes |
Showing 5 of 115 publications.
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Autoimmune hemolytic anemia | Annual incidence | 1-9 / 100 000 | United States | US | Unspecified |
| Autoimmune hemolytic anemia | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Autoimmune hemolytic anemia | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Autoimmune hemolytic anemia | Point prevalence | 1-5 / 10 000 | Denmark | Not stated | Unspecified |
| Autoimmune hemolytic anemia | Annual incidence | 1-9 / 100 000 | Europe | Not stated | Exact |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Autoimmune hemolytic anemia | 98375 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Autoimmune hemolytic anemia | 98375 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.